metabolized by conjugation to morphine-3-glucuronide (M3G) and morphine-6-glucuronide 71 (M6G). M3G is the main metabolite and has no pharmacological effect. These conjugates are 72 hydrophilic compounds and are mainly excreted in urine [1] [2] [3] [4] . It is known that the degradation of 73 DAM and 6OM is dependent on pH and temperature. Therefore, it is necessary to take prevention 74 measures in collecting samples to avoid the degradation [5] . Naloxone (NAL) is an opioid 75 antagonist and is used to reduce constipation caused by orally administered opioid therapy. NAL 76 concentrations in plasma are low after an oral administration because it is metabolized in the liver 77 primarily by glucuronidation [6, 7] . Naltrexone (NALT) is a competitive opioid antagonist that 78 blocks the pharmacologic effect of heroin, morphine and other opioids. NALT also undergoes a 79 significant first-pass metabolism [8, 9] .
80
In this work, all target compounds were determined and applied to a clinical trial in healthy (UV), diode-array (DAD), fluorescence [10] [11] [12] , gas chromatography with mass spectrometry 87 (MS) detection [13, 14] and HPLC tandem MS [1, [15] [16] [17] 
126
(1500 ng/mL) were prepared in human plasma. All of these solutions were freshly prepared daily. To evaluate stability in solution, working solutions were prepared and kept at room temperature 188 (25 ºC) for 6 hours and stored at 4-8ºC. Stock solutions were stored at 4-8ºC and quantified at 189 different times for more than 100 days to study long term stability. 
233
In this case, F could not be calculated because the intravenous data are not available, so the CL 234 and V z parameters were normalized to F.
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LC-MS/MS analysis 238
The MRM transitions, cone voltage and collision energy were optimized by direct infusion of each 239 analyte including the IS. Positive ion mode was used for MS detection of these compounds. Fig. 1 
240
shows the mass spectra of the protonated [M+H] + ion of heroin, its metabolites, NAL, NALT and 241 the IS. Only the major ion transitions were monitored (Table 1) . Although the same ion transition 242 was used for monitoring both M3G and M6G, their separation was possible by HPLC.
243
The main challenge during method development was to find the best conditions for the predictions than an unweighted model for all compounds (bias from the calibration curves is less 295 than 15% for all calibration points and the precision of three replicates is less than 15%). 
LLOQ, Precision and accuracy 297
The method was found to be highly accurate and precise. The mean accuracies of the quality 298 controls ranged between -3.6% and 4.0%, and the intra-and inter-assay precisions (CV) were < 299 11.5% for all the analytes. For all compounds, the LLOQ was 10 ng/mL in human plasma 300 showing acceptable accuracies within the range of -4.5% to 6.9% and precisions below 12.3%. Table 2 .
304
Working solutions were found to be stable at least for 6 hours at room temperature, and stock 305 solutions of each compound were stable for more than 100 days when stored at 4ºC in the fridge.
306
However, the internal standard solution was stable for only 14 days after storage in the refrigerator 307 at 4ºC and for 6 hours at room temperature. In human plasma, the results of long-term stability 308 were found to be within ±15% accuracy, indicating that all compounds are stable for more than 309 three months at -80ºC. Additionally, no detectable degradation was observed after three freeze-310 thaw cycles for all compounds. Similar results were observed on-instrument stability when 311 samples were stored in the autosampler for at least 20 hours at 10ºC. The stability during sample 312 processing was evaluated for 6 hours using an ice-bath (0 ºC) and all compounds were stable 313 under these conditions. M a n u s c r i p t 13 3.3.5. Dilution Integrity 315
In the dilution integrity study, the precision was less than 6.5% and the accuracy was within the 316 range of -11.6% to 7.7% for all compounds. These results proved that the samples with higher 317 concentrations than the ULOQ could be diluted and re-analysed. The overall CV of the IS normalized matrix effect was within the acceptable limits (2.4-12.5%).
320
These data proved that the matrix effect in human plasma for all compounds was negligible in this 
Conclusions 360
In conclusion, a rapid, specific and precise LC-MS/MS method was developed and validated for 361 the simultaneous quantification of DAM, its main metabolites (6OM, MOR, M3G and M6G) and 362 NAL in human plasma using a small volume of sample (100 µL). In addition, this method was 363 used for the qualitative detection of NALT. A simple protein precipitation were used for pre-M a n u s c r i p t 15 saves time during samples preparation. Although evaporation and reconstitution were necessary 366 for the M3G and M6G extraction in plasma samples, good recoveries and negligible matrix effects 367 were observed by using protein precipitation for all compounds. Table 3 . Pharmacokinetic parameters in human plasma after an oral administration of DAM/NAL 458 formulation in healthy volunteers (n = 12, data are means ± standard deviations). 
459
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